The Lab by Evernorth

The Lab by Evernorth℠ is our immersive accelerator of market-disrupting insights and solutions. It’s where we use data and analytics to better identify and understand the health care challenges you and your members face today.

Male in lab coat talking with female at desk

Together, we can leverage this intelligence to create real-world solutions and prepare for what comes next.

Unlock new ways to improve health care

When we think about improving health care, our goal is to find new opportunities to reduce costs, increase quality, and create health care experiences that are truly equitable. We welcome you to partner with us as we pilot and develop ideas that close gaps in care, enhance member experience, and maximize business value. 

Using our insights, expertise, and relationships, we’ll work with you to innovate the future of health care that best suits you and your members.

Lab at Evernorth - female reviewing data with male

A curious, committed, and compassionate team

We bring our leading experts together and work alongside our clients and partners to pilot, perfect, and launch improvements to patient care. Meet our team:

Glen Stettin

Glen Stettin, MD

Sr. Vice President + Chief Innovation Officer, Evernorth

View Glen's Profile
headshot

Al DeCarlo

Vice President, Market Analytics

View Al's Profile
""

Urvashi Patel, PhD

Vice President, Data + Analytics, Evernorth Research Institute

View Urvashi's Profile
Viju Paul

Viju Paul, RPh

Vice President, Clinical Analytics

View Viju's Profile
Portrait of Krystal Salamon

Krystal Salamon

Principal, Innovation & New Solutions

View Krystal's Profile
headshot

Marie Vidaic, PharmD

Senior Director, Clinical Analytics

View Marie's Profile
Explore related insights
""
Article
PBMs and the drug pipeline: Anticipating tomorrow while affording today
October 04, 2024
Lab tech
Article
Biosimilars help lower costs and foster innovation in pharmacy benefits
September 30, 2024
Express Scripts by Evernorth
Article
Other voices: Consequences of the FTC’s biased attack on PBMs
September 27, 2024